Mizuho Reaffirms “Neutral” Rating for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “neutral” rating restated by analysts at Mizuho in a report released on Tuesday, Marketbeat reports. They presently have a $0.50 price objective on the stock. Mizuho’s target price points to a potential upside of 13.64% from the company’s current price.

A number of other equities research analysts have also issued reports on the stock. Guggenheim lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Jefferies Financial Group cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research report on Monday. TD Cowen downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the stock from $20.00 to $4.00 in a research note on Wednesday, September 2nd. Royal Bank Of Canada restated a “sector perform” rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Finally, Wall Street Zen raised shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $22.25.

Eyepoint Pharmaceuticals Trading Down 85.3%

Shares of Eyepoint Pharmaceuticals stock opened at $0.44 on Tuesday. Eyepoint Pharmaceuticals has a twelve month low of $0.40 and a twelve month high of $19.11. The firm has a market capitalization of $37.93 million, a PE ratio of -0.12 and a beta of 1.67. The firm’s 50-day moving average price is $4.77 and its 200 day moving average price is $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The firm had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, sell-side analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Trading of Eyepoint Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth $29,000. Janney Montgomery Scott LLC grew its holdings in shares of Eyepoint Pharmaceuticals by 14.8% in the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after purchasing an additional 3,900 shares during the period. Baird Financial Group Inc. grew its holdings in shares of Eyepoint Pharmaceuticals by 16.4% in the second quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock valued at $468,000 after purchasing an additional 4,613 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at about $72,000. Finally, Pictet Asset Management Holding SA acquired a new stake in Eyepoint Pharmaceuticals during the first quarter worth about $141,000. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint plans to reduce operating expenses and concentrate resources on its late-stage DURAVYU program for DME. The narrower focus could extend the company’s cash runway and preserve value in its remaining lead program. EyePoint Announces Strategic Prioritization
• Neutral Sentiment: Unusual options activity included purchases of 7,885 call contracts, approximately 69% above typical daily call volume. This may indicate speculative interest or expectations of a rebound, but it does not change the company’s fundamental outlook.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. The setback led the company to halt related clinical trials early, removing a major potential catalyst and raising doubts about the drug’s commercial prospects in the market. EyePoint Announces Topline Results from LUCIA
• Negative Sentiment: The company announced a 53% workforce reduction as part of its restructuring after the clinical-trial setback. Although the cuts should lower expenses, they also signal a substantially reduced operating plan and weaker near-term growth prospects. EyePoint Pharmaceuticals to Cut 53% of Workforce
• Negative Sentiment: Guggenheim downgraded EYPT from “buy” to “neutral,” while Jefferies moved from “buy” to “hold.” Jefferies assigned a $1.00 price target, implying substantial upside from the current level, but the downgrade reflects sharply reduced confidence following the LUCIA results.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses. The inquiry adds legal and reputational risk, although it does not establish wrongdoing. EyePoint Pharmaceuticals Investigation Notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.